Spyre Therapeutics SYRE has advanced 44.9% in the past three months, far outpacing the Zacks sub-industry’s 11.7% gain and the S&P 500’s 1.2% rise. That run has put the durability of the stock’s momentum in focus.
Positive ulcerative colitis data and several 2026 readouts support investor interest. At the same time, a clinical-stage pipeline and elevated valuation leave less room for disappointing efficacy, safety or differentiation.
Spyre's 3-Month Rally Meets a Catalyst-Heavy Setup
SPY002 delivered positive 12-week induction results in Part A of the phase II SKYLINE study. The anti-TL1A antibody produced a statistically significant 10.7-point reduction in Robart’s Histopathology Index, a measure of tissue-level inflammation in ulcerative colitis.
The study also showed a 33% clinical remission rate and 42% endoscopic improvement rate. SPY002 was generally well tolerated, with no drug-related serious adverse events reported, giving investors clinical evidence to weigh alongside the recent share-price move.
Spyre Therapeutics, Inc. Price and Consensus
Spyre Therapeutics, Inc. price-consensus-chart | Spyre Therapeutics, Inc. Quote
SYRE Has More Phase II Readouts Ahead in 2026
The next catalyst is Part A top-line data for SPY003 in ulcerative colitis, expected in the third quarter of 2026. SKYLINE Part B is also enrolling patients across monotherapy and combination arms, with induction data expected in 2027.
Beyond inflammatory bowel disease, the phase II SKYWAY study has completed enrollment across rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. Rheumatoid arthritis data are due in the third quarter, followed by psoriatic arthritis and axial spondyloarthritis results in the fourth quarter.
Spyre's Early UC Data Raise the Bar for Expectations
SPY001 and SPY002 have both generated encouraging phase II ulcerative colitis signals, while the broader SKYLINE strategy tests three validated inflammatory targets as monotherapies and pairwise combinations. Continued progress could strengthen the case for deeper, less frequent treatment approaches.
Competition also raises the differentiation threshold. AbbVie ABBV continues to generate IBD data for Skyrizi and Rinvoq. Johnson & Johnson JNJ is advancing JNJ-4804, a co-antibody therapy targeting IL-23 and TNF, after phase IIb results in ulcerative colitis and Crohn’s disease.
SYRE's Valuation Leaves Less Room for Clinical Missteps
SYRE trades at 9.45X trailing 12-month book value per share versus a five-year median of 2.71X. The premium puts more weight on upcoming readouts because the company still has no approved products or commercial revenues.
Disappointing efficacy, unexpected safety issues or insufficient differentiation could pressure the shares. Intense competition adds another layer of risk, even as Spyre’s multiple programs reduce dependence on any single experimental therapy.
SYRE's Mixed Scores Temper the Momentum Signal
SYRE’s setup remains balanced. A dense clinical calendar can keep attention on the pipeline, but valuation and development risk make execution across the next several readouts important.
The stock currently carries a Zacks Rank #3 (Hold). Its Momentum Score of A is favorable, but the Value Score of F, Growth Score of F and VGM Score of F show that the stock does not have broad support across the Zacks Style Scores. The combination tempers the momentum signal without establishing a clear directional call.You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.
Research Chief Names "Single Best Pick to Double"
From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.
This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.
Free: See Our Top Stock And 4 Runners UpWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Spyre Therapeutics, Inc. (SYRE): Free Stock Analysis Report
Johnson & Johnson (JNJ): Free Stock Analysis Report
AbbVie Inc. (ABBV): Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).